RESUMEN
ObjectiveTo explore the effects of ziprasidone and risperidone on cognitive inhibition function through visual pathway of patients with paranoid schizophrenia.MethodsIn the open-label,flexible-dosage trial,124 patients with paranoid schizophrenia were randomly divided into ziprasidone group (120-160 mg/d)and risperidone group(4-8 mg/d) for treatment of 8 weeks.They were assessed with computerized Color Word Test (CWT) and Continuous Performance Test(CPT) through visual pathway for cognitive inhibition function,Positive and Negative Syndrome Scale for efficacy on baseline and 8th weekend.ResultsAfter treatment with ziprasidone,the error number (3.12 ± 5.23 ),the time per correct answer( ( 1.92 ± 1.38 ) s) of CWT,as well as the doubledigit mistaken number (2.31 ± 3.76)and the three-figure mistaken number( 3.15 ±2.80) of CPT reduced more than those before medication ( (4.60 ± 6.80),( 2.74 ± 1.52 ) s,(3.85 ± 3.62 ),(4.42 ± 3.53 ) ) (P < 0.05 ).In risperidone.group,the double-digit mistake number of CPT(3.39 ± 3.59) after pharmacotherapy reduced more than that before pharmacotherapy(4.23 ± 3.88) (P< 0.05).After treatment the time per correct answer of CWT and the mistaken numbers of CPT in ziprasidone group were less than those in risperidone group(P< 0.05 ),meanwhile,the scores of PANSS in two groups were significantly lower than those before treatment (P < 0.01 ).ConclusionIt is effective for ziprasidone and risperidone to improve the function of cognitive inhibition on patients with paranoid schizophrenia,but there is more dramatic for ziprasidone in short-term treatment.
RESUMEN
Objective To investigate the association between serum cytokines and depression and understand the effect of sertraline on serum leveI of interleukin 2(IL-2),interleukin 6(IL-6),tumor necrosis factor-α(TNF-α)and C-reactive protein(CRP).Methods A total of 50 depressive patients(study group) and 25 healthy controls(control group)were included in this study.The levels of serum IL-2,IL-6 and TNF-α were measured by enzymatic-linked immunosorbent assay(ELISA)on baseline and after treatment,CRP were measured by scatter rate nephelometry.Depressive patients were assessed by Hamilton depression sere(HAMD)on baseline and after treatment.Results The levels of IL-2(41.4±15.7)pg/ml,IL-6(63.4±17.2)pg/ml,TNF-α(81.4±19.3)pg/ml and CRP(8.2±2.9)mg/L in study group were significantly higher than those in control group(13.2±4.6)pg/ml,(21.3±7.7)ps/ml,(35.1±7.8)ps/ml,(2.9±0.5)mg/L,(P<0.01).Compared with baseline,the levels of serum IL-2(20.1±9.1)ps/ml,IL-6(38.5±11.6)pg/ml,TNF-a(49.5±12.6)pg/ml and CRP(4.2±1.6)mg/L after treatment by sertraline decreased significantly(P<0.01).In study group,there were significant positive correlations between the serum level of IL-2,IL-6,TNF-α and present age,the total score of HAMD(P<0.05,P<0.01).There were significant positive correlations between variation rates of serum IL-2,IL-6,TNF-αand reduction rate of HAMD(P<0.05,P<0.01).Conclusion The serum levels of IL-2,IL-6,TNF-α and CRP increased in patients with depression.Sertraline may affect depressive patients'serum levels of IL-2,IL-6,TNF-αand CRP.
RESUMEN
Objective: To investigate the quality of life of patients with chronic prostatitis. Methods: Two hundred patients were included and tested with WHOQOL-100 . Results: Compared with normal controls, the following aspects had no significant difference, including energy and fatigue, appearance and status, working activity, daily life and environment. There were significant difference to controls in other 6 fields and 20 aspects. The major factors that do harm to QOL include satisfaction on life, income and depression. Conclusion: It should deserve the clinician's attention that the QOL of patients with chronic prostatitis is greatly lower than that of the normal controls.